Immunogenicity of Viral Vaccines in the Italian Military.
HAV
adults
influenza
measles
military
mumps
polio
rubella
vaccines
varicella
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
17 Jan 2021
17 Jan 2021
Historique:
received:
29
11
2020
revised:
09
01
2021
accepted:
12
01
2021
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
23
1
2021
Statut:
epublish
Résumé
Military personnel of all armed forces receive multiple vaccinations and have been doing so since long ago, but relatively few studies have investigated the possible negative or positive interference of simultaneous vaccinations. As a contribution to fill this gap, we analyzed the response to the live trivalent measles/mumps/rubella (MMR), the inactivated hepatitis A virus (HAV), the inactivated trivalent polio, and the trivalent subunits influenza vaccines in two cohorts of Italian military personnel. The first cohort was represented by 108 students from military schools and the second by 72 soldiers engaged in a nine-month mission abroad. MMR and HAV vaccines had never been administered before, whereas inactivated polio was administered to adults primed at infancy with a live trivalent oral polio vaccine. Accordingly, nearly all subjects had baseline antibodies to polio types 1 and 3, but unexpectedly, anti-measles/-mumps/-rubella antibodies were present in 82%, 82%, and 73.5% of subjects, respectively (43% for all of the antigens). Finally, anti-HAV antibodies were detectable in 14% and anti-influenza (H1/H3/B) in 18% of the study population. At mine months post-vaccination, 92% of subjects had protective antibody levels for all MMR antigens, 96% for HAV, 69% for the three influenza antigens, and 100% for polio types 1 and 3. An inverse relationship between baseline and post-vaccination antibody levels was noticed with all the vaccines. An excellent vaccine immunogenicity, a calculated long antibody persistence, and apparent lack of vaccine interference were observed.
Identifiants
pubmed: 33477366
pii: biomedicines9010087
doi: 10.3390/biomedicines9010087
pmc: PMC7829820
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Defence
ID : D85D10000250001
Références
J Infect Dis. 1999 Dec;180(6):2018-22
pubmed: 10558961
J Infect Dis. 2011 Dec 15;204(12):1879-85
pubmed: 21998477
Clin Immunol. 2010 Feb;134(2):113-20
pubmed: 19846344
JAMA. 2000 Oct 25;284(16):2059
pubmed: 11042753
Clin Immunol. 2018 Oct;195:18-27
pubmed: 30036638
Clin Infect Dis. 2008 Aug 1;47(3):401-9
pubmed: 18558875
Lancet. 2019 Jul 13;394(10193):148-158
pubmed: 31174831
Lancet. 2003 Sep 27;362(9389):1065-71
pubmed: 14522539
Epidemiol Infect. 2002 Dec;129(3):543-50
pubmed: 12558337
J Infect Dis. 1996 Nov;174 Suppl 3:S295-7
pubmed: 8896533
Vaccine. 2015 Jun 4;33(24):2842-8
pubmed: 25131729
Curr Opin Pediatr. 1999 Feb;11(1):14-20
pubmed: 10084078
Vaccines (Basel). 2018 May 21;6(2):
pubmed: 29883414
Euro Surveill. 2009 Mar 12;14(10):
pubmed: 19317984
J Infect Dis. 2020 Mar 2;221(6):902-909
pubmed: 31112277
Expert Rev Vaccines. 2019 Mar;18(3):209-223
pubmed: 30806110
Hum Vaccin Immunother. 2019;15(5):1135-1138
pubmed: 30779686
Lancet. 2014 Oct 25;384(9953):1505-12
pubmed: 25018120
Front Immunol. 2019 Nov 12;10:2556
pubmed: 31781095
Clin Exp Immunol. 2014 Jul;177(1):287-94
pubmed: 24666311
J Travel Med. 2017 Jul 1;24(4):
pubmed: 28375507
Clin Immunol. 2017 Aug;181:60-66
pubmed: 28625884
J Infect Dis. 2008 Apr 1;197(7):950-6
pubmed: 18419470
Immunol Cell Biol. 2019 Jul;97(6):577-585
pubmed: 30791143
Pediatr Infect Dis J. 1994 May;13(5):348-55
pubmed: 8072815
J Med Virol. 2018 Aug;90(8):1418-1422
pubmed: 29663458
Lancet Infect Dis. 2012 Feb;12(2):128-35
pubmed: 22071249
Adv Immunol. 1968;8:81-127
pubmed: 4874538
Front Immunol. 2018 Jun 21;9:1397
pubmed: 29977239
Infect Immun. 1998 May;66(5):2093-8
pubmed: 9573094
J Infect Dis. 2020 Feb 18;221(5):721-728
pubmed: 31580436
PLoS One. 2016 Feb 22;11(2):e0149642
pubmed: 26901877
Clin Infect Dis. 2016 May 1;62(9):1111-1118
pubmed: 27060790
Wkly Epidemiol Rec. 2016 Mar 25;91(12):145-68
pubmed: 27039410
Vaccine. 2019 Mar 22;37(13):1775-1784
pubmed: 30797639
East Mediterr Health J. 2016 Oct 02;22(7):547-551
pubmed: 27714749
Clin Exp Immunol. 2018 Dec;194(3):361-370
pubmed: 30099753
Clin Vaccine Immunol. 2012 Aug;19(8):1292-5
pubmed: 22739695
Emerg Infect Dis. 2005 Jul;11(7):1155-6
pubmed: 16032799
Vaccine. 2018 Mar 7;36(11):1435-1443
pubmed: 29428176
Future Microbiol. 2015;10(5):791-808
pubmed: 25824845
Vaccine. 2018 Oct 29;36(45):6718-6725
pubmed: 30269918
J Hyg (Lond). 1976 Apr;76(2):235-47
pubmed: 177700
Lancet. 1993 Jun 19;341(8860):1545-50
pubmed: 8099637
Emerg Infect Dis. 1998 Oct-Dec;4(4):704-5
pubmed: 9866755
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
Vaccine. 2003 Sep 8;21(25-26):3530-3
pubmed: 12922079
JAMA. 1994 Sep 21;272(11):885-9
pubmed: 8078167
Hum Vaccin Immunother. 2018;14(9):2248-2253
pubmed: 29771600
JAMA. 2019 Dec 17;322(23):2276
pubmed: 31846022
J Infect Dis. 1979 Feb;139(2):225-7
pubmed: 220335
J Infect Dis. 2001 Oct 1;184(7):817-26
pubmed: 11528592
Vaccine. 2020 Feb 24;38(9):2172-2182
pubmed: 32008879
Vaccine. 2001 Feb 28;19(15-16):2006-11
pubmed: 11228371
Infez Med. 2016 Sep 1;24(3):230-3
pubmed: 27668904
Bull World Health Organ. 1976;54(3):275-8
pubmed: 191208
Can J Infect Dis. 2000 May;11(3):159-63
pubmed: 18159284
Science. 2014 Aug 22;345(6199):922-5
pubmed: 25146288
Hum Vaccin Immunother. 2013 Feb;9(2):405-8
pubmed: 23291930
N Engl J Med. 2004 Nov 25;351(22):2286-94
pubmed: 15525713
Vaccines (Basel). 2020 Feb 03;8(1):
pubmed: 32028593
JAMA. 2002 Mar 6;287(9):1114-5
pubmed: 11879107